Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer

Shanon Lacy, Antonio Lopez-Beltran, Gregory T. MacLennan, Stephanie R. Foster, Rodolfo Montironi, Liang Cheng

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Bladder cancer remains one of the most common and expensive cancers to treat worldwide. Numerous molecular markers are being investigated as possible ways to decrease health care costs, increase patient survival and prognosis, and increase sensitivity in screening tests. Several genetic markers have emerged as potential therapeutic targets and have provided new theories concerning the origins and progression of these tumors. Future classifications of bladder tumors should be based on the understanding of disease processes and should incorporate these emerging biomarkers for stratification of tumors into different prognostic groups.

Original languageEnglish (US)
Pages (from-to)5-16
Number of pages12
JournalAnalytical and Quantitative Cytology and Histology
Volume31
Issue number1
StatePublished - Feb 1 2009

Keywords

  • Biomarkers
  • Bladder cancer
  • Molecular genetics

ASJC Scopus subject areas

  • Anatomy
  • Histology

Fingerprint Dive into the research topics of 'Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer'. Together they form a unique fingerprint.

  • Cite this